Brief by Shorts91 Newsdesk / 05:51am on 30 Sep 2025,Tuesday Health & Wellness
India’s drug regulator, CDSCO, has approved Ozempic (semaglutide), a once-weekly injectable by Danish firm Novo Nordisk, for managing Type 2 diabetes and aiding weight management. Novo Nordisk India MD Vikrant Shrotriya called it a “much-needed move” to modernize chronic disease care. Ozempic complements existing treatments like oral semaglutide and Wegovy for advanced obesity management. With semaglutide’s patent set to expire in March 2026, generic versions could enhance accessibility and affordability in India. Amid rising lifestyle-related illnesses, Ozempic’s launch is a key step toward expanding effective treatment options for diabetes and obesity patients nationwide.
